Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Policy / Pricing

Trump backs psychedelics for mental health in new executive order

 April 20, 2026

Pharmaceutical Technology

Trump’s executive order sets out to speed up the review of psychedelics, while supporting research into this burgeoning field.

Policy / PricingNeuroscienceRead full story

Post navigation

UCB to purchase Neurona and NRTX-1001 for $1.15bn →
← AZ is three for three with COPD hope tozorakimab

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com